Tian et al., 2011 - Google Patents
Effects of interferon-α/β on HBV replication determined by viral loadTian et al., 2011
View HTML- Document ID
- 1618720514394553354
- Author
- Tian Y
- Chen W
- Ou J
- Publication year
- Publication venue
- PLoS pathogens
External Links
Snippet
Interferons α and β (IFN-α/β) are type I interferons produced by the host to control microbial infections. However, the use of IFN-α to treat hepatitis B virus (HBV) patients generated sustained response to only a minority of patients. By using HBV transgenic mice as a model …
- 230000000694 effects 0 title abstract description 91
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse Transcribing DNA Viruses
- C12N2730/00011—Reverse Transcribing DNA Viruses
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Tian et al. | Effects of interferon-α/β on HBV replication determined by viral load | |
| Tan et al. | When hepatitis B virus meets interferons | |
| Guo et al. | HBV core protein allosteric modulators differentially alter cccDNA biosynthesis from de novo infection and intracellular amplification pathways | |
| Allweiss et al. | Therapeutic shutdown of HBV transcripts promotes reappearance of the SMC5/6 complex and silencing of the viral genome in vivo | |
| Qi et al. | Recombinant covalently closed circular hepatitis B virus DNA induces prolonged viral persistence in immunocompetent mice | |
| Yin et al. | Hepatitis E virus persists in the presence of a type III interferon response | |
| Sato et al. | The RNA sensor RIG-I dually functions as an innate sensor and direct antiviral factor for hepatitis B virus | |
| Lucifora et al. | Direct antiviral properties of TLR ligands against HBV replication in immune-competent hepatocytes | |
| He et al. | Hepatitis D virus infection of mice expressing human sodium taurocholate co-transporting polypeptide | |
| Sajid et al. | The functional and antiviral activity of interferon alpha-inducible IFI6 against hepatitis B virus replication and gene expression | |
| Liu et al. | Alpha-interferon suppresses hepadnavirus transcription by altering epigenetic modification of cccDNA minichromosomes | |
| Addison et al. | Half-life of the duck hepatitis B virus covalently closed circular DNA pool in vivo following inhibition of viral replication | |
| Williams et al. | Hepatitis delta virus proteins repress hepatitis B virus enhancers and activate the alpha/beta interferon-inducible MxA gene | |
| Mao et al. | Indoleamine 2, 3-dioxygenase mediates the antiviral effect of gamma interferon against hepatitis B virus in human hepatocyte-derived cells | |
| Robek et al. | Lambda interferon inhibits hepatitis B and C virus replication | |
| Suárez-Amarán et al. | A new HDV mouse model identifies mitochondrial antiviral signaling protein (MAVS) as a key player in IFN-β induction | |
| Li et al. | Inhibition of hepatitis B virus replication by MyD88 involves accelerated degradation of pregenomic RNA and nuclear retention of pre-S/S RNAs | |
| Shen et al. | Hepatitis B virus persistence in mice reveals IL-21 and IL-33 as regulators of viral clearance | |
| Thi et al. | ARB-1740, a RNA interference therapeutic for chronic hepatitis B infection | |
| Li et al. | Interferon and interferon-stimulated genes in HBV treatment | |
| Winer et al. | Preclinical assessment of antiviral combination therapy in a genetically humanized mouse model for hepatitis delta virus infection | |
| Yu et al. | Hepatitis B virus e antigen activates the suppressor of cytokine signaling 2 to repress interferon action | |
| Ullah et al. | Antiviral activity of interferon alpha-inducible protein 27 against hepatitis B virus gene expression and replication | |
| Hao et al. | Inhibition of hepatitis B virus gene expression and replication by hepatocyte nuclear factor 6 | |
| Nakagawa et al. | Targeted induction of interferon-λ in humanized chimeric mouse liver abrogates hepatotropic virus infection |